Publication | Open Access

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Hematological MalignancyInterim AnalysisLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunologyClinical TrialsHematologyImmune Checkpoint InhibitorPharmacotherapyImmunotherapyOncologyVersus FludarabineHealth Sciences